Introduction {#s1}
============

Myotonic dystrophies (DM) are caused by repeat expansions in non-coding regions of the *DMPK* (type 1, DM1) and *CNBP* (type 2, DM2) genes. The transcribed, repeat-containing RNA forms hairpin structures which yield a strong interaction with certain RNA binding proteins. Patient cells accumulate foci containing this RNA and its interacting proteins. Amongst these interacting proteins are MBNL-proteins, which are involved in the regulation of alternative splicing. The accumulation of these proteins on the repeat RNA leads to them not being available for normal splicing so that a general mis-splicing ("spliceopathy") appears to occur with a shift to embryonic splice variants.

Clinically, DM is a progressive multisystemic disorder characterized by myotonia, muscle weakness, cataracts, and cardiac arrhythmia that can evolve to cardiomyopathy, insulin insensitivity and diabetes, testicular failure, and hypogammaglobulinemia (Udd and Krahe, [@B24]; Wenninger et al., [@B25]). The predominant muscle involvement brands DM as the most frequent muscular dystrophy in adulthood. Expansions of a CTG repeat in the 3\' UTR of the *DMPK* gene cause DM1 (Fu et al., [@B7]). Up to 35 of these CTG repeats are considered to be normal, 35 to 49 repeats are a premutation, and 50 or more CTG triplets are considered to be disease causing. There is a rough correlation between repeat tract length and disease severity in DM1. The longer the CTG repeats the more severe the disease. Between 50 and \~150 repeats have been observed in patients with mild phenotype and \~100 to \~1000 repeats were identified in patients with classical DM, while more than 1000 CTG-triplets result in congenital DM, the most severe form of the disease (De Antonio et al., [@B4]).

Muscle differentiation defects have been described for DM1 (Furling et al., [@B8]; Mastroyiannopoulos et al., [@B16]), but it is unclear if the observed nuclear envelope alterations in DM1 myoblasts (Meinke et al., [@B17]) contribute to these defects in a similar manner as they do to nuclear envelope linked disease (Meinke and Schirmer, [@B19]). The most visible NE alterations are invaginations, which have been previously observed in DM1 fibroblasts (Rodriguez et al., [@B22]), and down-regulation of the lamins A and B1 (Meinke et al., [@B17]). We found a correlation between *DMPK* repeat length and the number of nuclei with NE invaginations (Meinke et al., [@B17]). With the aim to investigate which factors---apart from lamins---contribute to these structures, we screened a set of selected NE transmembrane proteins (NETs) for altered distribution in DM1 patients.

NETs have been linked to a wide range of disorders which include several myopathies (Meinke and Schirmer, [@B19]). In the light of the NE aberrations observed in DM1 myoblasts and myotubes (Meinke et al., [@B17]), NETs are possible candidates to contribute to DM1 muscle pathology. We decided to test the proteins emerin, LBR, TMEM38a, TMEM70, SUN1, SUN2, nesprin 1, and nesprin 2 for their localization and expression in primary DM1 myoblasts compared to controls. All of these proteins are NETs expressed in muscle (Wilkie et al., [@B26]; Korfali et al., [@B13]). Of these selected NETs, muscular dystrophies are linked to emerin (Bione et al., [@B1]), nesprin 1 and nesprin 2 (Zhang et al., [@B27]), as well as SUN1 and SUN2 (Meinke et al., [@B18]). SUN1, SUN2, nesprin 1, and nesprin 2 are all core components of the LINC (linker of nucleo- and cytoskeleton) complex (Crisp et al., [@B3]), while emerin is also involved in connecting the nucleus to the cytoskeleton (Salpingidou et al., [@B23]). The NETs Tmem38a and LBR are involved in genome organization (Holmer and Worman, [@B12]; Robson et al., [@B21]). Nesprins1 and 2 encompass several proteins due to having many splicing isoforms, some of which are specifically up-regulated during muscle differentiation (Duong et al., [@B5]).

Further indication for a possible NE involvement comes from myotonic dystrophy protein kinase (DMPK), the protein encoded by the *DMPK* gene, which has been reported to localize to the NE. DMPK has been identified at the NE in HeLa cells as well as in C2C12 mouse myoblasts and neonatal rat cardiac myocytes (Harmon et al., [@B10], [@B11]) and reduced DMPK levels in DM1 patients have been observed (Fu et al., [@B6]). However, if haploinsufficiency of DMPK is a relevant factor in DM1 pathology remains unclear as two different DMPK-knockout mouse models show either a late onset progressive myopathy or no muscular phenotype at all (Reddy et al., [@B20]; Carrell et al., [@B2]).

Materials and methods {#s2}
=====================

Patients and controls
---------------------

Primary human myoblasts were obtained from the Muscle Tissue Culture Collection (MTCC) at the Friedrich-Baur-Institute (Department of Neurology, Ludwig-Maximilians-University, Munich, Germany). All control and patient materials were obtained with written informed consent of the donor. Ethical approval for this study was obtained from the ethical review committee at the Ludwig-Maximilians-University, Munich, Germany (reference 45--14). Repeat length was diagnosed on DNA extracted from blood. DM1 patients had the following DMPK repeat lengths: DM1-1 240-430; DM1-2 400-600; DM1-3 1100-1300; DM1-4 1500. The patient cell lines used are identical to those where a repeat-length depending enrichment of nucleoplasmic reticuli was seen (Meinke et al., [@B17]).

Tissue culture
--------------

Myoblasts were grown in tissue culture using skeletal muscle cell growth medium (PeloBiotech, Munich, Germany). Myoblasts were kept from reaching confluency to avoid differentiation. Passage numbers were matched for controls and patient cells for the respective experiments, throughout all experiments passage numbers 8 to 10 have been used. Coverslips for myoblast immunohistochemistry were fixed at about 60--70 % confluence. Cell lysates for Western blot were taken at the same confluence, all at an average of 3 days of culturing after the last splitting. All samples were taken at least two passages after thawing.

For differentiation confluent myoblasts were cultivated for 7 days in DMEM containing 5% horse serum.

Immunohistochemistry
--------------------

Myoblasts were fixed with methanol (−20°C). Primary antibodies used for staining include: lamin A/C 4A7, emerin 5D10, nesprin 1 8C3 (provided by Glenn E. Morris), nesprin 1, nesprin 2 (provided by Didier Hodzic), Sun1 Atlas (HPA008346), Sun2 11208, LBR 11745, TMEM70 (provided by Eric C. Schirmer) and TMEM38a Milipore (06-1005). All secondary antibodies were Alexafluor conjugated. DNA was visualized with DAPI (4,6-diamidino-2 phenylindole, dihydrochloride).

Microscopy and image analysis
-----------------------------

All images were obtained using an Olympus FluoView FV1000/BX 61microscope equipped with a 1.42 NA 60x objective and 3x zoom magnification. Image analysis was performed using ImageJ software.

Protein extracts
----------------

Myoblasts were washed with 1x PBS and trypsinized. Cell suspensions were inactivated with 10% FCS containing DMEM, collected in 1.5 ml tubes, centrifuged and washed twice in PBS. Cell pellets were directly dissolved in 10 mM Tris/HCl pH 7.6 1 % SDS lysis buffer containing protease inhibitors (cOmplete Tablets EDTA-free Roche 04 693 132 001).

For myotube extracts we first separated the myotubes using a minimal trypsin treatment to detach myotubes that were then gently centrifuged to sediment myotubes and separate them from remaining mono-nucleated cells: after this we used the same protocol as for myoblasts.

Western blotting
----------------

Proteins from whole protein extracts were separated by SDS gel electrophoresis using 4--15% TGX (BioRad \#456-8087) and self-prepared gels. Western blotting was performed using the Trans-Blot® TurboTM system (BioRad). Proteins were transferred to low fluorescent PVDF membranes (part of Trans-Blot® TurboTM RTA Transfer Kit \#170-4274). Membranes were blocked with 5% BSA or 5% skim milk in 1xTBS/0.1% Tween®20. Primary antibodies used were: lamin A/C 4A7, emerin 5D10, nesprin 1 8C3 (provided by Glenn E. Morris), nesprin 1, nesprin 2 (provided by Didier Hodzic), Sun1 Atlas (HPA008346), Sun2 11208, LBR 11745, TMEM70 (provided by Eric C. Schirmer), and TMEM38a Millipore (06-1005). As loading controls for quantification, mouse anti-GAPDH (Milipore \#MAB374), rabbit anti-GAPDH (Cell Signaling D16H1; XP \#5174) and goat anti-GAPDH (Thermo PA1-9046) were used. Secondary antibodies used were: donkey anti-mouse IRDye 680RD, donkey anti-mouse IRDye 800CW, donkey anti-rabbit IRDye 680RD, donkey anti-rabbit IRDye 800 CW, and donkey anti-goat HRP (Dianova 705-035-003). For chemiluminescence detection we used Weststar Supernova (Cyanagene XLS3). All Western blot images were obtained using a Licor FC. Quantification was done using the Licor ImageStudio Software. Western blots were repeated at least twice to confirm the results (Figure [S1](#SM1){ref-type="supplementary-material"}: complete blots).

Results {#s3}
=======

First, we tested the expression levels of the NETs emerin, LBR, SUN2, TMEM70, and TMEM38a in four DM1 patient-derived primary myoblasts of different *DMPK* repeat length and compared them to four controls (Figure [1A](#F1){ref-type="fig"}).

![Expression and localization of nesprin1 and nesprin2 primary myoblasts and myotubes. Western Blot, quantification and immunofluorescence staining of primary control and DM1 myoblasts and myotubes for nesprin1 **(A)** and nesprin2 **(B)**. DM1 samples are ordered according their diagnosed repeat length from left (small repeat) to right (long repeat). Scale bar 10 μm. The lanes for DM1-3 and DM1-4 have been rearranged for the nesprin1 blots to allow a presentation according to repeat length (indicated by black boxes). For original blots see supplemental material.](fphys-09-01532-g0001){#F1}

The range of emerin expression levels within the set of patient-derived myoblasts is no greater than the expression range of the controls. This is also the case for LBR (Figure [1A](#F1){ref-type="fig"}). However, for SUN2 expression decreased with increasing repeat length. Nonetheless, compared to controls these changes seem to be within the normal expression range for SUN2. The same tendency can be observed for TMEM70; also here the expression is within the control range. For TMEM38a we see a tendency for the \~35 kDa band to increase with increasing repeat length, but also without deviation from the control range.

The immunofluorescence stainings for these NETs show, similar to the Western blots, no big differences between patients and controls in their localization (Figure [1B](#F1){ref-type="fig"}). Emerin, LBR, SUN2, and SUN1 antibodies stained the NE in both patients and controls. In addition, NE invaginations were stained by these four proteins in the patient samples. For TMEM38a and TMEM70 we did not observe NE staining in either patient or control myoblasts, consistent with their induction and NE localization occurring during myogenesis (data not shown). The only difference is that in the controls lines we see spots within the nucleus stained by the TMEM38a antibody. These spots seem to be reduced in patient cells (Figure [1B](#F1){ref-type="fig"}).

Due to the fact that some nesprin isoforms are up-regulated during muscle differentiation (Duong et al., [@B5]), we decided to test the expression of the nesprins in both myoblasts and myotubes of patients and controls (Figure [2](#F2){ref-type="fig"}). There are two skeletal muscle specific isoforms of nesprin 1 and 2, nesprin-1-alpha-2 (N1-α2, \~111 kDa) and nesprin-2-alpha-1 (N2-α1, \~72 kDa). Other detected bands are likely degradation products (Duong et al., [@B5]). For nesprin 1, we used two different antibodies: N1-α2 polyclonal and 8C3 monoclonal. In myoblasts both antibodies detect the possible giant isoform (300+ kDa) and the N1-α2 antibody detects in addition the muscle-specific 111 kDa band. The 8C3 antibody shows that nesprin1 giant is down-regulated in the DM1 patients and the N1-α2 antibody shows a similar result for the possible giant isoform, although not as clearly. In myotubes several additional bands are detected, but all are comparable to controls. However, there is a tendency for decreased expression of these isoforms with increased repeat length. Immunofluorescence staining with the N1-α2 antibody shows no obvious differences between controls and patients (Figure [2A](#F2){ref-type="fig"}).

![Expression and localization of different nuclear envelope proteins in myoblasts. **(A)** Western Blot and quantification of primary control and DM1 myoblasts for emerin, LBR, Sun2 TMEM70, and TMEM38a. DM1 samples are ordered according their diagnosed repeat length from left (small repeat) to right (long repeat). The lanes for DM1-3 and DM1-4 have been rearranged for the LBR, SUN2, TMEM70, and TMEM38a blots to allow a presentation according to repeat length (indicated by black boxes). For original blots see supplemental material. **(B)** Immunofluorescence staining of primary control and DM1 myoblasts for emerin, LBR, Sun2 TMEM38a TMEM70 and Sun1. Scale bar 10 μm.](fphys-09-01532-g0002){#F2}

For nesprin 2 we did not detect any expression changes between controls and patients in the myoblasts, but in myotubes there is also the tendency of a \~250 kDa band to decrease with increasing repeat length in the patients; however, as observed with the other proteins, this decrease is still within the range observed in controls. Immunofluorescence staining shows a weaker NE staining compared to nesprin 1 but no differences between controls and patients (Figure [2B](#F2){ref-type="fig"}).

Discussion {#s4}
==========

Based on our prior observation of NE alterations in DM1 myoblasts (Meinke et al., [@B17]), we investigated NETs regarding their expression and localization to explore their possible contribution to these structural changes. In myoblasts we found no localization changes for any of the investigated NETs (emerin, LBR, SUN1, SUN2, TMEM38a, TMEM70, nesprin 1, and nesprin 2). However, this does not exclude a contribution of the NE in DM1. A study of NETs in Emery-Dreifuss muscular dystrophy (EDMD) primary myoblasts showed that NETs are inconsistent markers for this disease (Le Thanh et al., [@B14]) despite the fact that all identified EDMD causing mutations are in NE proteins. The missing NE staining of TMEM38a in myoblasts as well as the observed speckles inside the nucleus are consistent with other published data, although the NE localization could be confirmed in muscle fibers (Le Thanh et al., [@B14]). The same is probably the case for TMEM70. The observed tendency of reduced expression with increasing repeat length within the patients for SUN2, TMEM70 and to some degree as well emerin and the \~30 kDa band detected by the TMEM38a antibody might reflect the fact that not all DM1 myoblast nuclei have invaginations. Therefore, this might reflect changes in a subpopulation of cultured cells.

The decreased expression of nesprin 1 giant in DM1 myoblasts might be a contributory factor for the NE invaginations as nesprins are thought to form a network around the nucleus, thus contributing to its stability (Lu et al., [@B15]). However, it will be necessary to undertake further investigations to confirm this. The expression of smaller nesprin 1 and 2 isoforms during differentiation shows a similar tendency as the expression of the NETs SUN2, TMEM70, emerin and the possible TMEM38a isoform: reduced expression with increasing repeat length while still being in the range of the controls.

Overall the accumulation of small expression changes in several NETs could have an effect on NE mechanical stability, resulting in the NE invaginations observed in the patient cells. The expression changes observed for the nesprin 1 giant isoform could be contributory not only to the NE deformations but also to the disease phenotype, consistent with reported NE aberrations from nesprin 1 mutations linked to EDMD (Zhang et al., [@B27]) and spinocerebellar ataxia (Gros-Louis et al., [@B9]).

Conclusion {#s5}
==========

Changes in NET expression levels may contribute to NE alterations observed in DM1 primary myoblasts. Several muscle NETs showed expression changes which appear to correlate with *DMPK*-repeat length. The giant isoform of nesprin 1 seems to be a good candidate for further analysis regarding its potential contribution to DM1 NE alterations and pathology.
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